New understanding about calcific aortic stenosis and opportunities for pharmacologic intervention.

This review article will discuss aortic stenosis, the evolving studies defining the cellular mechanisms and the potential for medical therapies for the treatment of this disease.
Currently, the only therapy for these patients is surgical valve replacement. In the past decade there has been a change in the paradigm towards our understanding of the cellular biology of this disease process. Studies in laboratories across the world have demonstrated that this disease has an active biology and that this biology may be targeted with medical therapies similar to that of vascular atherosclerosis.
Calcific aortic stenosis is the third most common form of cardiovascular disease in the USA. It has replaced rheumatic heart disease in prevalence in western countries due to improved access to healthcare and the widespread use of antibiotics.
AuthorsLuis M Moura, Kameswari Maganti, Jyothy J Puthumana, F Rocha-Gonçalves, Nalini M Rajamannan
JournalCurrent opinion in cardiology (Curr Opin Cardiol) Vol. 22 Issue 6 Pg. 572-7 (Nov 2007) ISSN: 0268-4705 [Print] United States
PMID17921746 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Aortic Valve Stenosis (drug therapy, epidemiology, surgery)
  • Calcinosis (drug therapy, epidemiology, surgery)
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
  • Hypercholesterolemia (drug therapy, epidemiology)
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: